CorVista Health and Mayo Clinic Collaborate to Enhance Pulmonary Hypertension Diagnosis
CorVista Health has announced a collaboration with Mayo Clinic to advance the diagnosis and management of pulmonary hypertension (PH) through next-generation, non-invasive diagnostics. The partnership aims to evaluate the effectiveness of the CorVista-PH test, which has been cleared by the FDA, in improving the detection and referral accuracy for patients suspected of having PH. Pulmonary hypertension is a serious cardiovascular condition characterized by elevated pressure in the pulmonary arteries, often leading to delayed diagnosis due to overlapping symptoms with other diseases. The CorVista-PH test utilizes machine-learned algorithms to analyze cardiac and hemodynamic signals, offering a new approach to cardiovascular diagnostics. The collaboration will involve a prospective observational study to assess the test's impact when used alongside current diagnostic methods, with the goal of achieving earlier and more accurate detection of PH. 
